New combo pill plus insulin shows promise for type 2 diabetes
NCT ID NCT02081599
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding the diabetes pill teneligliptin to insulin helps people with type 2 diabetes control their blood sugar better. 148 Japanese adults who were already on a stable insulin dose took either teneligliptin or a placebo for 16 weeks, with an extension up to 52 weeks. The main goal was to see if HbA1c (a measure of average blood sugar) improved more with the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teneligliptin (a diabetes pill that helps lower blood sugar)
What this could lead to
If it works, this could offer a new combination option for people with type 2 diabetes who need better blood sugar control despite using insulin.
What could go wrong
This is a completed Phase 4 study in a specific population (Japanese patients), so results may not apply to other groups. Adding another drug also raises the chance of side effects like low blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site
Chuo-ku, Tokyo, Japan